

Annexure : 1.0 (AF 1.0 / 003 / 1.0)

Application Form for Initial Review

Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur

**IEC Ref. No.** *(For office use):IEC/XXXX(year)/YY(month)/number*

General Instructions : a) Tick one or more options as applicable. Mark NA if not applicable

Logo of the Institute

b) Attach additional sheets if required

# SECTION A - BASIC INFORMATION

1. ADMINISTRATIVE DETAILS

(a) Name of Organization: ………………………………………………………………………………………………..........................……………………..........

(b) Name of Ethics Committee: …………………………………………………………………………………………..................................………..…………

(c) Title of the study/Thesis/disseratation/project/article………………………………………………………………………………………………………………..

(d) Department/Division: (e) Date of submission:

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

(f) Type of review requested1 :

Exemption from review  Expedited review  Full committee review 

(g): Nature of Proposed research: part of academic curriculum/individual research/ collaborative research (intramural:intradepartmental/interdepartmental/extramural): Name of the departments involved:……………………………….

Name of Course: ……………………………Year of admission………………………...........Year of expected Completion………………………..

…………………………………………………………………………………………………………………………………................................…………………………..

(h) Protocol number (If any or NA): ……………………………………………………… Version number: ……………………………….......…...………

1. Details of Investigators:

|  |  |  |  |
| --- | --- | --- | --- |
| Name | Designation and Qualification | Department and Institution | Phone, email & address for communication***2*** |
| Principal Investigator/student/fellow | | | |
|  |  |  |  |
| Co-investigator/student/fellow/Guide/CoGuide | | | |
|  |  |  |  |

(j) Number of Active Studies where applicant is a Principal Investigator:………….

(k) Duration of the study: ……………………………(months)

(l) Does the research needs registration/permission of any agency like CTRI/DCGI/SHMRC etc: Yes/No( please Specify)……………………..

( attach relevant document)…………………………………………………………………………………………………………………….

***1****Refer to National Ethical Guidelines for Biomedical and Health Research Involving Human Participants 2017 on Page 36 Table 4.2. for types of review*

***2****Include telephone/mobile, fax numbers and email id*

*Version 2.0 01*

1. FUNDING DETAILS AND BUDGET

(a) Total estimated budget for site: …………………………………………………………………………………………………….......................……………

At site…………………………….................... In India…………………………...…………… Globally ………………........…...................................

(b) Self-funding  Institutional funding  Funding agency *(Specify)* 

( if Funding from Outside India then comment on FCRA regulations)…………………………………………………………………..

SECTION B - RESEARCH RELATED INFORMATION

1. OVERVIEW OF RESEARCH (attach a copy of protocol as per format)

(a) Lay summary3 (within 300 words): ……………………..................................…………………………………………….....………………………...

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

(b) Type of study: (tick all possible)

|  |  |  |
| --- | --- | --- |
| Basic Sciences  Clinical |  Cross Sectional |  |
| Retrospective  Epidemiological/ |  Case Control |  |
| Prospective  Public Health | Cohort |  |
| Qualitative  Socio-behavioural |  Systematic Review |  |
| Quantitative  Biological samples/ Data |  |  |
| Mixed Method  Any others *(Specify)* |  |  |

..........................................................................................................................................................………............…………………................

1. METHODOLOGY
   1. Sample size/ number of participants *(as applicable)*

At site…………………………….................... In India…………………………...…………… Globally ………………........…...................................

Control group………………………………………………………………… Study group ……………………………….…......….........................………

Justification for the sample size chosen (100 words); In case of qualitative study, mention the criteria used for saturation ...................………………………………………………………………………………………………………………………………….........................

...............…………………………………………………………………………………………...………………………………………………….....................….......…

………..................................…………………………………………………………….....……………….…………………………………………………………………

………..................................…………………………………………………………….....………………….………………………………………………………………

………..................................…………………………………………………………….....…………….…………………………………………………………...………

………..................................…………………………………………………………….....…………….…………………………………………………………...………

*3Summarize in the simplest possible way such that a person with no prior knowledge of the subject can easily understand it.*

*Version 2.0 02*

* 1. Is there an external laboratory/outsourcing involved for investigations?4 Yes  No  NA 
  2. How was the scientific quality of the study assessed?

Independent external review  Review by sponsor/Funder  Review within PI’s institution 

Review within multi-centre  No review 

research group Date of review:

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

Comments of Departmental Committee/Scientific Advisory Committee, if any (100 words): ( attach copy)

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

SECTION C: PARTICIPANT RELATED INFORMATION

1. RECRUITMENT AND RESEARCH PARTICIPANTS
   1. Type of participants in the study:

Healthy volunteers  Patients  Vulnerable persons/ Special groups 

Others  *(Specify)* .................................................................................................…........…………...........................

Who will do the recruitment? ……………………………………………………………………………………………………………………......................

Participant recruitment methods used:

Posters/ 

leaflets/Letters

TV/Radio ads/  Social media/ Institution website

Patients / Family/ Friends 

visiting hospitals

Telephone 

Others  *(Specify)* ……………………………………...................................................................................................……

* 1. i. Will there be vulnerable persons / special groups involved ? Yes  No  NA 

ii. If yes, type of vulnerable persons / special groups

Children under 18 yrs  Pregnant or lactating women  Differently abled (Mental/Physical)  Employees/Students/Nurses/Staff  Elderly  Institutionalized  Economically and socially disadvantaged  Refugees/Migrants/Homeless  Terminally ill (stigmatized or rare diseases) 

Any other *(Specify)*:  ……………………......................................................................................

iii. Provide justification for inclusion/exclusion …………………………………………………………………………..................………………..

…………………………………………………………………………………………………………………………………………………………….…....…………………

…………………………………………………………………………………………………………………………………………………………….…....………………… iv. Are there any additional safeguards to protect research participants?..........................................................................

…………………………………………………………………………………………………………………………………………………………….…....…………………

…………………………………………………………………………………………………………………………………………………………….…....…………………

*4If participant samples are sent outside for investigations, provide details of the same and attach relevant documentation such as an MTA / MoU*

*Version 2.0 03*

* 1. Is there any reimbursement to the participants? Yes  No 

If yes, Monetary  Non-monetary  *Provide details*

………………………………………………………………………………………………………………………………….……………………….………………………………

……………………………………………………………………………………………….....………………………………….……………………….………………….........

* 1. Are there any incentives to the participants? Yes  No 

If yes, Monetary  Non-monetary  *Provide details*

……………………………………………………………………………………………………………………………………………………………………………..……………

…………………………………………………………………………………………………………………………....................................................................….

* 1. Are there any participant recruitment fees/ incentives for the study provided to the PI / Institution?

If yes, Monetary  Non-monetary  *Provide details* Yes  No 

……………………………………………………………………….….………………………………………………………………………………………………………………

…………………………………………………………………………...……………………………………………………….……………………….……………….…….......

1. BENEFITS AND RISKS
   1. i. Are there any anticipated physical/social/psychological discomforts/ risk to participants? Yes  No 

If yes, categorize the level of risk5 :

Less than Minimal risk  Minimal risk 

Minor increase over minimal risk or low risk  More than minimal risk or high risk 

ii. Describe the risk management strategy: …………………………………………………………………………………....................................

..…………………………………………………..…………….….……………………………………………………………………………………………….....………....

..…………………………………………………..…………….….……………………………………………………………………………………………….....………....

* 1. What are the potential benefits from the study? For the participant

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Yes | No | If yes, | Direct | Indirect |
|      |      |  |      |      |

For the society/community For improvement in science

Please describe how the benefits justify the risks …………………………………………………………………………………………..……………

………………………………………………………………………….….…………………………………………………………………………………………….………………

………………………………………………………………………….….……………………………………………………………………………………………….……………

………………………………………………………………………….….……………………………………………………………………………………………….……………

* 1. Are adverse events expected in the study6 ? Yes  No  NA  Are reporting procedures and management strategies described in the study? Yes  No  If Yes, Specify …………………………………………………………………................................……………………………………………………………………

…………………......……………………………………………………….….……………………………………………………………………………………………………….

..................................................................................................................................................................................................................

1. INFORMED CONSENT
   1. Are you seeking waiver of consent? If yes, please specify reasons and skip to item no. 8 Yes  No 

.....................………………………………………………………………………………………………………………………….…………….....…………..………………

.....................………………………………………………………………………………………………………………………….…………....………………………………

*5For categories of risk refer to National Ethical Guidelines for Biomedical & Health Research Involving Human Participants 2017, Page 6 Table 2.1*

*6The term adverse events in this regard encompass both serious and non-serious adverse events. Version 2.0 04*

* 1. Version number and date of Participant Information Sheet (PIS): Please attach Copy

Version number and date of Informed Consent Form (ICF): Please attach Copy

* 1. Type of consent planned for :

Signed consent  Verbal/Oral consent  Witnessed consent 

Audio-Video (AV) 

consent

Consent from LAR/NR 

(If so, specify from whom)

(LAR/NR: legally applicable representative/nominated representative) Other 

For children<7 yrs 

parental/LAR consent

Verbal assent from  minor (7-12 yrs) along with parental consent

Written assent from  minor (13-18 yrs) along with parental consent

*(specify)* ..............................................................................................................................................................................................

* 1. Who will obtain the informed consent?

PI/Co-I  Nurse/Counselor  Research Staff  Other  (*Specify)* ………….............................……...

Any tools to be used ……………………………………………………………………………………………………………............................……………....

* 1. Participant Information Sheet (PIS) and Informed Consent Form (ICF)

English  Local language  Other  *(Specify)*………………………........................................……...

List the languages in which translations were done Assamese/Hindi/Bengali/Others(specify)………………………………….

If translation has not been done, please justify …………………………………………………………….....................….….………………......

………………………………………………………………………………………………………………………………………………………………...............................

* 1. Provide details of consent requirements for previously stored samples if used in the study7

....................………………………………………………………………………………………………………………………….…………….....…………..………………

....................………………………………………………………………………………………………………………………….…………....………………………………

* 1. Elements contained in the Participant Information Sheet(PIS) and Informed Consent Form (ICF)

Simple language 

Risks and discomforts  Alternatives to participation  Right to withdraw 

Benefits 

Purpose and procedure 

Others(Specify) 

Data/ Sample sharing 

Need to recontact 

Confidentiality 

Storage of samples  Return of research results  Payment for participation 

Compensation for study related injury  Statement that consent is voluntary  Commercialization/ Benefit sharing  Statement that study involves research  Use of photographs/ Identifying data  Contact information of PI and Member  Secretary of IEC

.........................………………………………………………………………………………………………………………………….…………....………………………………

1. PAYMENT/COMPENSATION
   1. Who will bear the costs related to participation and procedures8 ?

PI/CoPI  Institution  Sponsor  Other agencies  *(specify)*

………………………………….......................................................................................................................................................................…

* 1. Is there a provision for free treatment of research related injuries? Yes  No  N/A 

If yes, then who will provide the treatment? …………………………………………………………………………………………..........................

* 1. Is there a provision for compensation of research related SAE? If yes, specify. Yes  No  N/A 

Sponsor  Institutional/Corpus fund  Project grant  Insurance 

* 1. Is there any provision for medical treatment or management till the relatedness is determined for injury to the participants during the study period? If yes, specify. Yes  No  N/A 

.........................………………………………………………………………………………………………………………………….…………………………………………

* 1. Is there a provision for ancillary care for unrelated illness during the study period? If yes, please specify.

Yes  No  N/A 

*7Information on re-consent requirements can be found at National Ethical Guidelines for Biomedical and Health Research Involving Human Participants 2017, Page 54 in Section 5.8.*

*8Enclose undertaking from PI confirming the same*

*Version 2.0 05*

1. STORAGE AND CONFIDENTIALITY
   1. Identifying Information: Study Involves samples/data. *If Yes, specify* Yes  No  NA  Anonymous/Unidentified  Anonymized: Reversibly coded  Irreversibly coded  Identifiable  If identifiers must be retained, what additional precautions will be taken to ensure that access is limited /data is safeguarded? (e.g. data stored in a cabinet, password protected computer etc.) …………………………………………………….

....…………………………………………………………………………………………………………………………..……………...............................…………………

....…………………………………………………………………………………………………………………………..……………...............................…………………

....…………………………………………………………………………………………………………………………..……………...............................…………………

....…………………………………………………………………………………………………………………………..……………...............................………………… (b) Who will be maintaining the data pertaining to the study? …………..……….......................………………………………………………. (c) Where will the data be analyzed9 and by whom? ……………………….……………………..............................……………………………..

(d) For how long will the data be stored? ………………………………………...………………………........................…………………………………

(e) Do you propose to use stored samples/data in future studies? Yes  No  Maybe 

If yes, explain how you might use stored material/data in the future?...................................................................................

....…………………………………………………………………………………………………………………………..……………...............................…………………

....…………………………………………………………………………………………………………………………..……………...............................…………………

....…………………………………………………………………………………………………………………………..……………...............................…………………

SECTION D: OTHER ISSUES

1. PUBLICATION, BENEFIT SHARING AND IPR ISSUES
   1. Will the results of the study be reported and disseminated? If yes, specify. Yes  No  NA 

.…………......……………………………………………………….….………………………………………………………………………………………………………………

.…………......……………………………………………………….….………………………………………………………………………………………………………………

* 1. Will you inform participants about the results of the study? Yes  No  NA 
  2. Are there any arrangements for continued provision of the intervention for participants, if effective, once the study has finished? If yes describe in brief (Max 50 words) Yes  No  NA 

.…………......……………………………………………………….….………………………………………………………………………………………………………………

.…………......……………………………………………………….….………………………………………………………………………………………………………………

* 1. Is there any plan for post research benefit sharing with participants? If yes, *specify* Yes  No  NA 

.…………......……………………………………………………….….………………………………………………………………………………………………………………

.…………......……………………………………………………….….………………………………………………………………………………………………………………

* 1. Is there any commercial value or a plan to patent/IPR issues? If yes, please provide details Yes  No  NA 

.…………......……………………………………………………….….………………………………………………………………………………………………………………

* 1. Do you have any additional information to add in support of the application, which is not included elsewhere in the form? If yes, provide details. Yes  No 

.…………......……………………………………………………….….………………………………………………………………………………………………………………

.…………......……………………………………………………….….………………………………………………………………………………………………………………

.…………......……………………………………………………….….………………………………………………………………………………………………………………

.…………......……………………………………………………….….………………………………………………………………………………………………………………

9*For example, a data entry room, a protected computer etc.*

*Version 2.0 06*

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

SECTION E: DECLARATION AND CHECKLIST 10

|  |  |
| --- | --- |
| 11. DECLARATION (Please tick as applicable) | |
|  | I/We certify that the information provided in this application is complete and correct. |
|  | I/We confirm that all investigators have approved the submitted version of proposal/related documents |
|  | I/We confirm that this study will be conducted in accordance with the latest ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants and other applicable regulations and guide- lines 2017. |
|  | I/We confirm that this study will be conducted in accordance with the Drugs and Cosmetics Act 1940 and its Rules 1945 as amended from time to time, GCP guidelines and other applicable regulations and guidelines. |
|  | I/We will comply with all policies and guidelines of the institute and affiliated/collaborating institutions where this study will be conducted. |
|  | I/We will ensure that personnel performing this study are qualified, appropriately trained and will adhere to the provisions of the IEC approved protocol. |
|  | I/We declare that the expenditure in case of injury related to the study will be taken care of. |
|  | I/We confirm that an undertaking of what will be done with the leftover samples is provided, if applicable. |
|  | I/We confirm that we shall submit any protocol amendments, adverse events report, significant deviations from protocols, progress reports and a final report and also participate in any audit of the study if needed. |
|  | I/We confirm that we will maintain accurate and complete records of all aspects of the study. |
|  | I/We will protect the privacy of participants and assure confidentiality of data and biological samples. |
|  | I/We hereby declare that I/any of the investigators, researchers and/or close relative(s), have no conflict of interest (Financial/Non-Financial) with the sponsor(s) and outcome of study. |
|  | I/We have the following conflict of interest (PI/Co-I):  1. .....................................................................................................................................................................................................  .....................................................................................................................................................................................................  2. ....................................................................................................................................................................................................  ...................................................................................................................................................................................................... |
|  | I/We declare/confirm that all necessary government approvals will be obtained as per requirements wherev- er applicable. |
| Name of PI: ………………....................................................................................................................................……………......................  Signature: ........................……………………………….............................................................................................  Name of Co-PI: ..................................................................................................................................…………………………….................  Signature: ........................……………………………….............................................................................................  Name of Guide: ..................................................................................................................................…………………………….................  Signature: ........................……………………………….............................................................................................  Name of HOD: ..................................................................................................................................…………………………….................  Signature: ........................………………………………............................................................................................. | |

(Format adapted from ICMR10)

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

*Version 2.0 07*

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 12. CHECKLIST | | | | | | | | | | | | | |
| S. No | Items | | | | | | | | Yes | No | NA | Enclosure No | EC Remarks (If applicable) |
| ADMINISTRATIVE REQUIREMENTS | | | | | | | | | | | | | |
| 1 | Cover letter | | | | | | | |  |  |  |  |  |
| 2 | Brief CV of all Investigators | | | | | | | |  |  |  |  |  |
| 3 | Good Clinical Practice (GCP) training of investigators in last 3 years | | | | | | | |  |  |  |  |  |
| 4 | Approval of scientific advisory committee | | | | | | | |  |  |  |  |  |
| 5 | EC clearance of other centers\* | | | | | | | |  |  |  |  |  |
| 6 | Agreement between collaborating partners\* | | | | | | | |  |  |  |  |  |
| 7 | MTA between collaborating partners\* | | | | | | | |  |  |  |  |  |
| 8 | Insurance policy/certificate | | | | | | | |  |  |  |  |  |
| 9 | Evidence of external laboratory credentials in case of an externally outsourced laboratory study QA/QC certification | | | | | | | |  |  |  |  |  |
| 10 | Copy of contract or agreement signed with the sponsor or donor agency | | | | | | | |  |  |  |  |  |
| 11 | Provide all significant previous decisions (e.g. those leading to a negative decision or modified protocol) by other ECs/Regulatory authorities for proposed study (whether in same location or elsewhere) and modification(s) to protocol | | | | | | | |  |  |  |  |  |
| PROPOSAL RELATED | | | | | | | | | | | | | |
| 12 | Copy of the detailed protocol11 | | | | | | | |  |  |  |  |  |
| 13 | Investigators Brochure (If applicable for drug/biologicals/device trials) | | | | | | | |  |  |  |  |  |
| 14 | Participant Information Sheet (PIS) and Participant Informed Consent Form (ICF)(English and translated) | | | | | | | |  |  |  |  |  |
| 15 | Assent form for minors (12-18 years) (English and Translated) | | | | | | | |  |  |  |  |  |
| 16 | Proforma/Questionnaire / Case Report Forms (CRF)/ Interview guides/ Guides for Focused Group Discussions (FGDs) (English and translated) | | | | | | | |  |  |  |  |  |
| 17 | Advertisement/material to recruit participants (fliers, posters etc) | | | | | | | |  |  |  |  |  |
| PERMISSION FROM GOVERNING AUTHORITIES | | | | | | | | | | | | | |
|  | **Other permissions** | **Required** | | **Not required** | | **Received** | | **Applied dd/ mm/yy** | **EC Remarks** | | | | |
| 18 | CTRI |  | |  | |  | |  |  | | | | |
| 19 | DCGI |  | |  | |  | |  |  | | | | |
| 20 | HMSC |  | |  | |  | |  |  | | | | |
| 21 | NAC-SCRT |  | |  | |  | |  |  | | | | |
| 22 | ICSCR |  | |  | |  | |  |  | | | | |
| 23 | RCGM |  | |  | |  | |  |  | | | | |
| 24 | GEAC |  | |  | |  | |  |  | | | | |
| 25 | BARC |  | |  | |  | |  |  | | | | |
| 26 | Tribal Board |  | |  | |  | |  |  | | | | |
| 27 | Others (Specify) |  | |  | |  | |  |  | | | | |
| ANY OTHER RELEVANT INFORMATION/DOCUMENTS RELATED TO THE STUDY | | | | | | | | | | | | | |
|  | **Item** | | **YES** | | **NO** | **NA** | **Enclosure no.** | | **EC remarks** | | | | |
| 28 |  | |  | |  |  |  | |  | | | | |
| 29 |  | |  | |  |  |  | |  | | | | |

*\*For multicentre research.*

*MTA-Material transfer agreement; CTRI-Clinical Trial Registry-India; DCGI-Drug Controller General of India; HMSC- Health Ministry’s Screening Committee; NAC-SCRT- National Apex Committee for Stem Cell Research and Therapy; IC-SCR-Institutional committee for Stem Cell Research; RCGM- Review Com- mittee on Genetic Manipulation; GEAC- Genetic Engineering Approval Committee; BARC- Bhabha Atomic Research Centre*

11*Refer to National Ethical Guidelines for Biomedical and Health Research Involving Human Participants 2017, section 4 Page no. 35 Box 4.4(b)*

*Version 2.0 08*

Annexure



Annexure : 1.1 (AF 1.1 / 003 / 1.0)

Application Form for Expedited Review

Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur

*(Name of the Institution)* **IEC Ref. No.\*** *(For office use):*

1. Choose reasons why expedited review from EC is requested12 ?

Title of study: ………………………….......………...………………………………………………………......................………………...…………………………………..

………………………………………………………………………………………………………………………………………………….................................……………………

…………………………………………………………………………………………………………………………………………….................................………………………… Principal Investigator (Name, Designation and Affiliation): ……………………………………...................……………….....……………………....

……………………………………………………………………………………………………………………………………………............................……….....…………………

……………………………………………………………………………………………………………………………………………........……....................……….....……………

* 1. Involves non-identifiable specimen and human tissue from sources like blood banks, tissue banks and 

left-over clinical samples.

* 1. Involves clinical documentation materials that are non-identifiable (data, documents, records). 
  2. Modification or amendment to approved protocol (administrative changes/correction of typographical 

errors and change in researcher(s)).

* 1. Revised proposal previously approved through expedited review, full review or continuing review of 

approved proposal.

* 1. Minor deviation from originally approved research causing no risk or minimal risk. 
  2. Progress/annual report where there is no additional risk, for example activity limited to data analysis. 

Expedited review of SAEs/unexpected AEs will be conducted by SAE subcommittee.

* 1. For multicentre research where a designated EC has approved the proposal, a participating EC may  review participating centre specific information and modifications in the study proposal through full committee meeting/expedited review depending on the importance of local consent related issues involved specific to the centre.
  2. Research during emergencies and disasters (See Section 12 of ICMR Ethical Guidelines, 2017). 

ix. Any other (please specify) …………………………………………………………………………………………………...........................................…

.………………………………………………………………………………………………………………………………………........................................................

1. Is waiver of consent being requested? Yes  No 
2. Does the research involve vulnerable persons13 ? Yes  No 

If Yes give details: …………………………………………………………………………………………………...............................................................………

……………………………………………………………………………………………………………………………………………........................................................

……………………………………………………………………………………………………………………………………………........................................................

Signature of PI: ……………………………………………………………………………................…………........................…………

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

Comments of EC Secretariat: ……………………………………………………………………………............................................................……………

Signature of Member Secretary: ……………………………………………………..............…………….........................……

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

*12 Refer to National Ethical Guidelines for Biomedical & Health Research Involving Human Participants 2017, Page 51 Table 4.2*

Logo of the Institute

*13For details, refer to application for initial review, Section-C, 5(b)*

*\* In case this is first submission, leave it blank*

*Version 2.0*



Logo of the Institute

(Annexure 1.2 (AF 1.2/003/01.0)

Application Form for Exemption from Review

Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur

*(Name of the Institution)* **IEC Ref. No.** *(For office use):*

1. Choose reasons why exemption from ethics review is requested14?

Title of study: ………………………….......…………………………………………………………………......................………………………………………………..

…………………………………………………………………………………………………………………………………………………............................……………………

……………………………………………………………………………………………………………………………………………............................………………………… Principal Investigator (Name, Designation and Affiliation): ……………………………………...................……………………………………..

……………………………………………………………………………………………………………………………………………............................…………………………

……………………………………………………………………………………………………………………………………………........……....................……………………

|  |  |
| --- | --- |
| 1. Research on data in the public domain/ systematic reviews or meta-analyses 2. Observation of public behavior/ information recorded without linked identifiers and disclosure |    |
| would not harm the interests of the observed person |  |
| iii. Quality control and quality assurance audits in the institution |  |
| iv. Comparison among instructional techniques, curricula, or classroom management methods |  |
| v. Consumer acceptance studies related to taste and food quality |  |
| vi. Public health programmes by government agencies*15* |  |

vii. Any other (please specify in 100 words): ………………………………………………………………………………….…………………………………

……………………………………………………………………………………………………………………………………………........................................................

…………………………………………………………………………………………………………………………………………….........................................................

…………………………………………………………………………………………………………………………………………….........................................................

…………………………………………………………………………………………………………………………………………….........................................................

Signature of PI: …………………………………………………………………………….........................................……………………

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

Comments of EC Secretariat: ……………………………………………………………………………...........................................................……………

Signature of Member Secretary: ……………………………………………………..............…..........................………………

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

*14Select the category that applies best to your study and justify why you feel it should be exempted from review. For a detailed understanding of the type of studies that are exempt from review, refer to National Ethical Guidelines for Biomedical & Health Research Involving Human Participants 2017, Page 51 Table 4.2.*

*15Such as programme evaluation where the sole purpose of the exercise is refinement and improvement of the programme or monitoring (where there are no individual identifiers)*

*Version 2.0*



(Annexure 1.3 (AF/1.3/003/01.0)

Continuing Review / Annual report format

Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur

*(Name of the Institution)* **IEC Ref. No.** *(For office use):*

1. Date of EC Approval:

Title of study: ………………………….......………………………………………………………………......................…………………………………………………..

…………………………………………………………………………………………………………………………………………………............................……………………

……………………………………………………………………………………………………………………………………………............................………………………… Principal Investigator (Name, Designation and Affiliation): ……………………………………...................……………………………………..

……………………………………………………………………………………………………………………………………………............................…………………………

……………………………………………………………………………………………………………………………………………........……....................……………………

1. Date of Start of study:

Validity of approval: Proposed date of Completion:

Period of Continuing Report:

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

1. Does the study involve recruitment of participants?

---- to ------

Yes  No 

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

* 1. If yes, Total number expected…………………… Number Screened: …………………… Number Enrolled: ………................

Number Completed:……....………………...........……………………… Number on followup:…………….....….....…………………………….

* 1. Enrolment status – ongoing / completed/ stopped
  2. Report of DSMB16 Yes  No  NA

(d) Any other remark………………………………………………………………………………………………………………........................................…..…….

...……………......……………………………………………………….….……………………………………………………………………………………………….......…..

(e) Have any participants withdrawn from this study since the last approval? Yes  No  NA If yes, total number withdrawn and reasons: ……………………………………………………………………….....................................……..

…………………......……………………………………………………….….……………………………………………………………………………....…………………….

…………………......……………………………………………………….….……………………………………………………………………………....…………………….

1. Is the study likely to extend beyond the stated period ?17 Yes  No 

If yes, please provide reasons for the extension. …………….……………………………………………………………....................................……

…………………......……………………………………………………….….………………………………………………………………………………………………………..…..

………………………………………………………………………….….……………………………………………………….....……………………………………………..………

1. Have there been any amendments in the research protocol/Informed Consent Document (ICD) during the past approval period?

If No, skip to item no. 6 Yes  No 

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

* 1. If yes, date of approval for protocol and ICD :
  2. In case of amendments in the research protocol/ICD, was re-consent sought from participants? Yes  No If yes, when / how: …………………………………………………………………………………...........……………......................................................

.…………......……………………………………………………….….……………………………………………………………………………………………………….……

.……………………………………………………………….….……………………………………………………….....……………………………………………………..…

*16In case there is a Data Safety Monitoring Board (DSMB) for the study provide a copy of the report from the DSMB. If not write NA.*

Logo of the Institute

*17Problems encountered since the last continuing review application with respect to implementation of the protocol as cleared by the EC*

*Version 2.0*

1. Is any new information available that changes the benefit - risk analysis of human participants involved in this study? Yes  No 

If yes, discuss in detail: ………………………………………………………………………………………………………………..….....................................…….

…………………......……………………………………………………….….…………………………………………………………………..…………....……………………………

………………………………………………………………………….….……………………………………………………….....…………..………………..…………………………

1. Have any ethical concerns occurred during this period? Yes  No 

If yes, give details:.……………………………………………………………………………………………………………………..........................................………

…………………......……………………………………………………….….……………………………………………………………………….……....……………………………

1. (a) Have any adverse events been noted since the last review? Yes  No 

Describe in brief: …………………………………………………………………………………….......................................…….………………………………

....…………………......……………………………………………………….….……………………………………………………………………….……....…………………

....…………………......……………………………………………………….….……………………………………………………………………….……....…………………

1. Have any SAE’s occurred since last review? Yes  No 

If yes, number of SAE’s :………………………………...........……. Type of SAE’s: …………………..................….…………………..…………

....…………………......……………………………………………………….….……………………………………………………………………….……....…………………

....…………………......……………………………………………………….….……………………………………………………………………….……....…………………

1. Is the SAE related to the study? Yes  No 

Have you reported the SAE to EC? If no, state reasons Yes  No 

....…………………......……………………………………………………….….……………………………………………………………………….……....…………………

....…………………......……………………………………………………….….……………………………………………………………………….……....…………………

1. Has there been any protocol deviations/violations that occurred during this period?

If yes, number of deviations …………………………………………………………………………........................................………………….………………

Have you reported the deviations to EC? If no, state reasons Yes  No 

…………………......……………………………………………………….….………………………………………………….…………………………....……………………………

………………………………………………………………………….….…………………………………………….………….....…………………………..……………...…………

1. In case of multicenteric trials, have reports of off-site SAEs been submitted to the EC ? Yes  No  NA 
2. Are there any publications or presentations during this period? If yes give details Yes  No 

…………………......……………………………………………………….….………………………………….…………………………………………....……………………………

………………………………………………………………………….….………………………………….…………………….....…………………………..…………………………

Any other comments:……………………………………………………………….................................................……………………………....……………..…

……………………………………………………………………………………………………………….………...................................................……………........………

Signature of PI: ………………………………………………………….................……………………….......................………………

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

*Version 2.0*



(Annexure 1.4 (AF/1.4/003/01.0)

Application/Notification form for Amendments

Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur

*(Name of the Institution)* **IEC Ref. No.** *(For office use):*

1. Date of EC approval:

Title of study: ………………………….......………………………………………………………………......................…………………………………………………..

…………………………………………………………………………………………………………………………………………………............................……………………

……………………………………………………………………………………………………………………………………………............................………………………… Principal Investigator (Name, Designation and Affiliation): ……………………………………...................……………………………………..

……………………………………………………………………………………………………………………………………………............................…………………………

……………………………………………………………………………………………………………………………………………........……....................……………………

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

1. Details of amendm ent(s)

Date of start of study

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| S.No | Existing Provision | Proposed Amendment | Reason | Location in the protocol/ICD 18 |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

1. Impact on benefit-risk analysis Yes  No

If yes, describe in brief: ………………………………………………………………………………………………………………………………………....…....………

………………………………………………………………………………………………………………………………………………..................................................……

1. Is any reconsent necessary? Yes  No

If yes, have necessary changes been made in the informed consent? Yes  No

1. Type of review requested for amendment:

Expedited review (No alteration in risk to participants) 

Full review by EC (There is an increased alteration in the risk to participants) 

1. Version number of amended Protocol/Investigator’s brochure/ICD: ………………………………………………

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

Signature of PI: …………………………………………………………………….........................…………

*18Location implies page number in the ICD/protocol where the amendment is proposed.*

Logo of the Institute

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

*Version 2.0*



Logo of the Institute

(Annexure 1.5 9AF1.5/003/01.0)

Protocol Violation/Deviation Reporting Form (Reporting by case)

Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur

*(Name of the Institution)* **IEC Ref. No.** *(For office use):*

1. Date of EC approval Date of start of study

Title of study: ……………………….......…………………………………………………………………......................…………………………………………………...

…………………………………………………………………………………………………………………………………………………............................……...………………

……………………………………………………………………………………………………………………………………………............................………………………...… Principal Investigator (Name, Designation and Affiliation): ……………………………………...................…………………………………...…..

……………………………………………………………………………………………………………………………………………............................………………….....……

……………………………………………………………………………………………………………………………………………........……....................……………………...

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

1. Participant ID: Date of occurrence

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

3. Total number of deviations /violations reported till date in the study: ………………………....................................…………….........

1. Deviation/Violation identified by: Principal Investigator/study team  Sponsor/Monitor 

SAE Sub Committee/EC 

1. Is the deviation related to (Tick the appropriate box) :

|  |  |  |
| --- | --- | --- |
| Consenting |  Source documentation |  |
| Enrollment |  Staff |  |
| Laboratory assessment |  Participant non-compliance |  |
| Investigational Product  Safety Reporting |  Others *(specify)*   |  |

6. Provide details of Deviation/Violation: ………………………………………………………………………………….................................………………

………………………………………………………………………………………………………………………………………………..................................................……

………………………………………………………………………………………………………………………………………………..................................................……

………………………………………………………………………………………………………………………………………………..................................................……

7. Corrective action taken by PI/Co-I: …………………….………………………………………………………………………….................................……..

………………………………………………………………………………………………………………………………………………..................................................……

………………………………………………………………………………………………………………………………………………..................................................……

………………………………………………………………………………………………………………………………………………..................................................……

1. Impact on (if any): Study participant  Quality of data 
2. Are any changes to the study/protocol required? Yes  No If yes, give details…………………………………………….....................................…………………………….……………………………………………………….

………………………………………………………………………………………………………………………………………………....................................................…… Signature of PI: …………………………………………………………………………………

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

*Version 2.0*



Logo of the Institute

(Annexure 1.6 (AF 1.6/003/01.0)

Serious Adverse Event Reporting Format (Biomedical Health Research)

Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur

*(Name of the Institution)* **IEC Ref. No.** *(For office use):*

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Participant details :  Initials and ID | Age at the time of event | Gender | Weight: (Kgs) |
| ………………………………. | ………………………………. | Male  Female  | Height: (cms) |
| ………………………………. | ……………………………….. |  |  |

2. Suspected SAE diagnosis:……………………………………...................................………………………………………………………………………………….

Title of study: …………………………......…………………………………………………………………......................…………………………………………………

…………………………………………………………………………………………………………………………………………………............................……………………

……………………………………………………………………………………………………………………………………………............................………………………… Principal Investigator (Name, Designation and Affiliation): ……………………………………...................……………………………………..

……………………………………………………………………………………………………………………………………………............................…………………………

……………………………………………………………………………………………………………………………………………........……....................……………………

1. Date of onset of SAE: Describe the event 19:

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

…………………………………………………………………………...................

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

Date of reporting SAE: …………………………………………………………………………...................

…………………………………………………………………………...................

…………………………………………………………………………...................

…………………………………………………………………………...................

…………………………………………………………………………...................

…………………………………………………………………………...................

1. Details of suspected intervention causing SAE 20

………………………………………………………………………………………………………….......................................……………………………………………………

………………………………………………………………………………………………………….......................................……………………………………………………

………………………………………………………………………………………………………….......................................……………………………………………………

………………………………………………………………………………………………………….......................................……………………………………………………

………………………………………………………………………………………………………….......................................……………………………………………………

………………………………………………………………………………………………………….......................................……………………………………………………

1. Report type: Initial  Follow-up  Final  If Follow-up report, state date of Initial report

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

1. Have any similar SAE occurred previously in this study? If yes, please provide details. Yes  No

………………………………………………………………………………………………………….......................................……………………………………………………

………………………………………………………………………………………………………….......................................……………………………………………………

………………………………………………………………………………………………………….......................................……………………………………………………

………………………………………………………………………………………………………….......................................……………………………………………………

*19Duration, setting, site, signs, symptoms, severity, criteria for regarding the event serious*

*20Refers to research intervention including basic, applied and operational research or clinical research, except for investigational new drugs. If it is an academic clinical trial, mention name, indications, dosage, form and strength of the drug(s)*

*Version 2.0*

1. In case of a multi-centric study, have any of the other study sites reported similar SAEs ? (Please list number of cases with details if available)

.……………………………………………………………………………………………………………………………………………….......................................………………

………………………………………………………………………………………………………….......................................…………………………………...………………

1. Tick whichever is applicable for the SAE: (Kindly note that this refers to the Intervention being evaluated and NOT disease process)

A. Expected event  Unexpected event 

B.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Hospitalization |  | Increased Hospital Stay |  | Death |  | Congenital anoma- ly/birth defect |  |
| Persistent or signifi- cant disability/inca- pacity |  | Event requiring inter- vention (surgical or medical) to prevent SAE |  | Event which poses threat to life |  | Others |  |

………………………………………………………………………………………………………….......................................……………………………………………………

In case of death, state probable cause of death……………………………………………………………………..................................………….

C. No permanent/significant functional/cosmetic impairment  Permanent/significant functional/cosmetic impairment  Not Applicable 

1. Describe the medical management provided for adverse reaction (if any) to the research participant. (Include infor- mation on who paid, how much was paid and to whom).

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Provide details of compensation provided / to be provided to participants (Include information on who pays, how much, and to whom)……………………………………………………………………………………………………………….......................................................

……………………………………………………………………………………………………………………………………………………………...........................................

1. Outcome of SAE

Fatal  Recovered 

Continuing  Unknown 

Recovering  Other *(specify)* 

........................................................................................................................................……………………………………........................................

1. Provide any other relevant information that can facilitate assessment of the case such as medical history

………………………………………………………………………………………………………….......................................……………………………………………………

………………………………………………………………………………………………………….......................................……………………………………………………

………………………………………………………………………………………………………….......................................……………………………………………………

1. Provide details about PI’s final assessment of SAE relatedness to research.

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................………………….................................................. Signature of PI: …………………………………………………………………………………….

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

*Version 2.0*



(Annexure 1.7 (AF 1.7/003/01.0)

Premature Termination/Suspension/ Discontinuation Report Format

Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur

*(Name of the Institution)* **IEC Ref. No.** *(For office use):*

Title of study: ……………………….......…………………………………………………………………......................………………….……………………………..

…………………………………………………………………………………………………………………………………………………............................……………………

……………………………………………………………………………………………………………………………………………............................………………………… Principal Investigator (Name, Designation and Affiliation): ……………………………………...................……………………………………..

……………………………………………………………………………………………………………………………………………............................…………………………

……………………………………………………………………………………………………………………………………………........……....................……………………

1. Date of EC approval:

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

1. Date of last progress report submitted to EC:
2. Date of termination/suspension/discontinuation:

Date of start of study:

1. Tick the appropriate

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

Premature Termination  Suspension  Discontinuation 

Reason for Termination/Suspension/Discontinuation: ………………………………................................…………………………………………

………………………………………………………………………………………………………….......................................……………………………………………………

………………………………………………………………………………………………………….......................................……………………………………………………

………………………………………………………………………………………………………….......................................…………………………………………………… Action taken post Termination/ Suspension/Discontinuation (if any): ……………………………………………………………………………

………………………………………………………………………………………………………….......................................……………………………………………………

………………………………………………………………………………………………………….......................................……………………………………………………

………………………………………………………………………………………………………….......................................……………………………………………………

5. Plans for post study follow up/withdrawal21 (if any): ……………………................................……………………………………………………….

………………………………………………………………………………………………………….......................................……………………………………………………

…………………………………………………………………………………………………………............................................……………………………………………….

6. Details of study participants:

Total participants to be recruited: …….......……………. Screened: ………...........………… Screen failures:………..........……………..

Enrolled:………………............……….. Consent Withdrawn:…….......……………….. Reason (Give details): …………...……………..

………………………………………………………………………………………………………….......................................……………………………………………………

…………………………………………………………………………………………………………............................................……………………………………………….

Withdrawn by PI:…………............................………. Reason(Give details): ……………………………………………………………......………………

………………………………………………………………………………………………….......................................…………………………………………………….........

*21 Describe post-termination/suspension/ discontinuation follow up plans if any. Also describe any withdrawal plans for the study.*

Logo of the Institute

*Version 2.0*

Active on treatment: ……………..........… Completed treatment : ………..........…… Participants on follow-up: …………........……

Participants lost to follow up: ………………….......…… Any other: ……………..........……….. Number of drop outs:…………..............

Reasons for each drop-out: …………………………………………………………………………………………………………....................................………..

………………………………………………………………………………………………….......................................………………………….………………………….........

………………………………………………………………………………………………….......................................……………………….…………………………….........

………………………………………………………………………………………………….......................................……………….…………………………………….........

7. Total number of SAEs reported till date in the study: ……………………………………………………...……………...................................……

Have any unexpected adverse events or outcomes observed in the study been reported to the EC? Yes  No

1. Have there been participant complaints or feedback about the study? Yes  No If yes, provide details:……………………………………………………………………………………………………...................................………………………

…………………………………………………………………………………………………………………………………......................................……………………………

1. Have there been any suggestions from the SAE Sub Committee? Yes  No If yes, have you implemented that suggestion? Yes  No
2. Do the procedures for withdrawal of enrolled participants take into account their rights and welfare? Yes  No (e.g., making arrangements for medical care of research participants): If Yes, provide details

………………………………………………………………………………………………….......................................…………………………………………………….........

………………………………………………………………………………………………….......................................…………………………………………………….........

Summary of results (if any): ………………………………………………….………………………..................................……………………………………….

………………………………………………………………………………………………….......................................…………………………………………………….........

………………………………………………………………………………………………….......................................…………………………………………………….........

………………………………………………………………………………………………….......................................…………………………………………………….........

………………………………………………………………………………………………….......................................…………………………………………………….........

………………………………………………………………………………………………….......................................…………………………………………………….........

Signature of PI: …………………………………………………………………………………..............….

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

*Version 2.0*



Logo of the Institute

(Annexure 1.8 (AF 1.8/003/01.0)

Application Form for Clinical Trials

Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur

*(Name of the Institution)* **IEC Ref. No.** *(For office use):*

1. Type of clinical trial Regulatory trial  Academic trial 

Title of study: ……………………….......…………………………………………………………………......................…………………………………………………...

…………………………………………………………………………………………………………………………………………………............................……...………………

……………………………………………………………………………………………………………………………………………............................………………………...… Principal Investigator (Name, Designation and Affiliation): ……………………………………...................…………………………………...…..

……………………………………………………………………………………………………………………………………………............................………………….....……

……………………………………………………………………………………………………………………………………………........……....................……………………...

CTRI registration number: ……………… NABH accreditation number:...................... EC registration number:........................

1. If regulatory trial, provide status of CDSCO permission letter

Approved and letter attached  Applied, under process 

Not applied (State reason) ……………………………………………………………………………………………...................................................

1. Tick all categories that apply to your trial

Phase - I  Phase II 

Phase III  Phase IV or Post Marketing Surveillance 

|  |  |  |
| --- | --- | --- |
| Investigational medicinal products |  Investigational New drug |  |
| Medical devices |  New innovative procedure |  |
| Drug/device combination |  Bioavailability/Bioequivalence studies |  |
| Non-drug intervention |  Repurposing an existing intervention |  |
| Indian system of medicine (AYUSH) Phytopharmaceutical drug  Others (specify) | * Stem cells * Approved drug for any new indication * or new route of administration |    |

................……………………………………………………………………………………………...........................…………………..................................................

1. Trial design of the study
   1. Randomized  Factorial 

|  |  |  |
| --- | --- | --- |
| Non randomized |  Stratified |  |
| Parallel |  Adaptive |  |
| Cross-over |  Comparison trial |  |
| Cluster |  Superiority trial |  |
| Matched-pair |  Non-inferiority trial |  |
| Others *(specify)* |  Equivalence trial |  |

............……………………………………………………………………………………………...........................…………………..................................................

* 1. If there is randomization, how will the participants be allocated to the control and study group(s)?

............……………………………………………………………………………………………...........................…………………..................................................

............……………………………………………………………………………………………...........................…………………..................................................

* 1. Describe the method of allocation concealment (blinding / masking), if applicable.

............……………………………………………………………………………………………...........................…………………..................................................

............……………………………………………………………………………………………...........................…………………..................................................

*Version 2.0*

1. List the primary / secondary outcomes of the trial.

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Is there a Contract Research Organization (CRO) /Site Management Organisation (SMO) / Any other agency such as public relation/human resource? Yes  No 

If yes, Name and Contact details: ……………………………………………………………………………………………………..........................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................………………….................................................. State how the CRO/SMO/agency will be involved in the conduct of the trial (tick all that apply)

|  |  |  |
| --- | --- | --- |
| Project management |  Clinical and medical monitoring |  |
| Regulatory affairs |  Data management |  |
| Statistical support |  Medical writing |  |
| Site management |  Audits, quality control, quality assurance |  |
| Finance management |  Recruitment and training |  |
| Administrative support |  Others *(specify)* |  |

................……………………………………………………………………………………………...........................…………………..................................................

1. Please provide the following details about the intervention being used in the protocol
   1. Drug/s, device/s and/or biologics; if yes, provide regulatory approval details. Yes  No  NA 

............……………………………………………………………………………………………...........................…………………................................................

............……………………………………………………………………………………………...........................…………………................................................

* 1. Already approved drugs or a combination of two or more drugs with new indications / change in dosage form / route of administration. If yes, provide details. Yes  No  NA 

...........……………………………………………………………………………………………...........................………………….................................................

...........……………………………………………………………………………………………...........................………………….................................................

* 1. Provide contact details of who prepared and /or is manufacturing the drug/s, device/s and biologics.

................……………………………………………………………………………………………...........................…………………............................................

................……………………………………………………………………………………………...........................…………………............................................

* 1. Provide details of patent of the drug/s, device/s and biologics.

................……………………………………………………………………………………………...........................…………………............................................

................……………………………………………………………………………………………...........................…………………............................................

1. Describe in brief any preparatory work or site preparedness for the protocol? Yes  No  NA 

If yes, provide details (100words)……………………………………………………………………………………………......................................………….

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

*Version 2.0*

1. Is there an initial screening/ use of existing database for participant selection? Yes  No  NA 

If Yes, provide details22….……..………………………………………………………………………………………………………...................................………….

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Is there any anticipated incidence, frequency and duration of adverse events related to the intervention?

If yes, provide details of arrangements made to address them. Yes  No  NA 

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Does the study use a placebo?

If yes, justify the use of the placebo and risks entailed to participants. Yes  No  NA 

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Will current standard of care be provided to the control arm in the study? Yes  No  NA 

If no, please justify.

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Are there any plans to withdraw standard therapy during the study? If yes, please justify. Yes  No  NA 

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Are there any rules to stop the protocol in case of any adverse events? If yes, please specify. Yes  No  NA 

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Does the study have a Data and Safety Monitoring Plan? If no, please justify. Yes  No 

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

*22 In order to select participants for your protcol does the protocol require you to screen an initial population or refer to an existing database before shortlisting participants. If yes, provide details on the same*

*Version 2.0*

1. Participant Information Sheet(PIS) and Informed Consent Form (ICF)

English 

Other*(Specify)* 

Local language 

(certified that local version (s) is/are a true translation of the English version and

can be easily understood by the participants)

................……………………………………………………………………………………………...........................………………….................................................. List the languages in which translations were done ………………………………………………………………………….................................……

Justify if translation not done……………………………………………………………………………………………………………….....................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Involvement/consultation of statistician in the study design Yes  No  NA 
2. Is there any insurance coverage of the trial? If yes, provide details. Yes  No 

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

* 1. Is the PI registered with Medical Council of India (MCI) or the State Medical Council registration?

Please provide details. Yes  No 

.............................……………………………………………………………………………………………...........................………………….....................................

..............……………………………………………………………………………………………...........................…………………....................................................

* 1. Is the PI trained in GCP in last 3 years? If yes, Please enclose certificate Yes  No 

Signature of PI: …………………………………………………………………………………………………

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

*Version 2.0*



Title of study: .……………………….......…………………………………………………………………......................…………………………………………………...

…………………………………………………………………………………………………………………………………………………............................……...………………

……………………………………………………………………………………………………………………………………………............................………………………...… Principal Investigator (Name, Designation and Affiliation): ……………………………………...................…………………………………...…..

……………………………………………………………………………………………………………………………………………............................………………….....……

……………………………………………………………………………………………………………………………………………........……....................……………………...

Logo of the Institute

(Annexure 1.9 (AF 1.9/003/01.0)

Serious Adverse Event Reporting Format (Clinical trials)

Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur

*(Name of the Institution)* **IEC Ref. No.** *(For office use):*

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Participant details :  Initials and Case No./ | Age at the time of event | Gender | Weight: (Kgs) |
| Subject ID  ………………………………. | ………………………………. | Male  Female |  Height: (cms)   |
| ……………………………….. |  |  |  |
| 2. Report type: Initial  | Follow-up  Final  |  |  |

If Follow-up report, state date of Initial report

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

What was the assessment of relatedness to the trial in the initial report?

|  |  |  |
| --- | --- | --- |
| By PI – Related  | By Sponsor – Related  | By EC – Related  |
| Unrelated  | Unrelated  | Unrelated  |

3. Describe the event and specify suspected SAE diagnosis:……………………………………………...……………………………………….............

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Date of onset of SAE: Date of reporting:

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

1. Onset lag time after administration of intervention: Location of SAE (Clinic/Ward/Home/Other)

....………………………………………………………………………………. ......................................………………………………………………………………….

1. Details of suspected study drug/device/investigational procedure causing SAE:

I. Suspect study drug (include generic name) device/intervention: …………………………………….............................................…..

...........……………………………………………………………………………………………...........................…………………..................................................

II. Indication(s) for which suspect study drug was prescribed or tested: ……………...........................................……………………..

................……………………………………………………………………………………………...........................…………………..............................................

* 1. Route(s) of administration, daily dose and regimen, dosage form and strength : ……………………………………………………….

...........……………………………………………………………………………………………...........................…………………..................................................

* 1. Therapy start date: Stop date:

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

1. Was study intervention discontinued due to event? Yes  No 

*Version 2.0*

1. Did the reaction decline after stopping or reducing the dosage of the study drug / procedure? Yes  No 

If yes, provide details about the reduced dose...................................................................................................................................

1. Did the reaction reappear after reintroducing the study drug / procedure? Yes  No  NA 

If yes, provide details about the dose....................................................................................................................................................

1. Concomitant drugs history and lab investigations:

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

* 1. Concomitant drug (s) and date of administration:

...........……………………………………………………………………………………………...........................…………………................................................

...........……………………………………………………………………………………………...........................…………………................................................

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

* 1. Relevant test/laboratory data with dates:

...........……………………………………………………………………………………………...........................…………………................................................

...........……………………………………………………………………………………………...........................…………………................................................

* 1. Patient relevant history including pre-existing medical conditions (e.g. allergies, race, pregnancy, smoking, alcohol use, hepatic/ renal dysfunction etc)………………………….......................................................................................…………

...........……………………………………………………………………………………………...........................…………………................................................

...........……………………………………………………………………………………………...........................…………………................................................

1. Have any similar SAE occurred previously in this study? If yes, please provide details. Yes  No 

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Seriousness of the SAE:

|  |  |  |
| --- | --- | --- |
| Death |  Congenitial anomaly |  |
| Life threatening |  Required intervention to prevent |  |
| Hospitalization-initial or prolonged |  permanent impairment / damage |  |
| Disability |  Others *(specify)* |  |

........................................................................................................................................……………………………………........................................

1. Describe the medical management provided for adverse reaction (if any) to the research participant. (Include infor- mation on who paid, how much was paid and to whom).

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Outcome of SAE:

|  |  |  |
| --- | --- | --- |
| Fatal |  Recovered |  |
| Continuing |  Unknown |  |
| Recovering |  Other *(specify)* |  |

........................................................................................................................................……………………………………........................................

1. Was the research participant continued on the trial? Yes  No  NA 
2. Provide details about PI’s final assessment of SAE relatedness to trial.

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Has this information been communicated to sponsor/CRO/regulatory agencies? Yes  No 

Provide details if communicated (including date)

1. Does this report require any alteration in trial protocol? Yes  No 
2. Provide details of compensation provided / to be provided the participants (Include information on who pays, how much, and to whom)……………………………………………………………………………………………………………….......................................................

……………………………………………………………………………………………………………………………………………………………...........................................

Signature of PI: …………………………………………………………………………………………………

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

*Version 2.0*



Logo of the Institute

(Annexure 1.10 (AF 1.10/003/01.0)

Application Form for Human Genetics Testing Research

Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur

*(Name of the Institution)* **IEC Ref. No.** *(For office use):*

1. Describe the nature of genetic testing research being conducted.

Title of study: ………………………….......…………………………………………………………………......................…………………………………………………..

…………………………………………………………………………………………………………………………………………………............................……...………………

……………………………………………………………………………………………………………………………………………............................………………………...… Principal Investigator (Name, Designation and Affiliation): ……………………………………...................…………………………………...…..

……………………………………………………………………………………………………………………………………………............................………………….....……

……………………………………………………………………………………………………………………………………………........……....................……………………...

(e.g.- screening/gene therapy/newer technologies/human embryos/foetal autopsy)

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Does the study involve pretest and post-test counselling? If yes, please describe. Yes  No  NA 

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Explain the additional safeguards provided to maintain confidentiality of data generated.

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. If there is a need to share the participants’ information/investigations with family/community, is it addressed in the informed consent? Yes  No  NA 

If findings are to be disclosed, describe the disclosure procedures (e.g. genetic counseling)

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Is there involvement of secondary participants? Yes  No  NA 

If yes, will informed consent be obtained? State reasons if not. Yes  No  NA 

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. What measures are taken to minimize/mitigate/eliminate conflict of interest?

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Is there a plan for future use of stored samples for research? Yes  No  If yes, has this been addressed in the informed consent ? Yes  No  Signature of PI: …………………………………………………………………………………………………

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

*Version 2.0*



Logo of the Institute

(Annexure 1.11 (AF 1.11/003/01.0)

Application Form for Socio-Behavioural and Public Health Research

Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur

*(Name of the Institution)* **IEC Ref. No.** *(For office use):*

1. Data collection method used in the study

Title of study: .……………………….......…………………………………………………………………......................…………………………………………………...

…………………………………………………………………………………………………………………………………………………............................……...………………

……………………………………………………………………………………………………………………………………………............................………………………...… Principal Investigator (Name, Designation and Affiliation): .……………………………………...................…………………………………...…..

………………………………………………………………………………………………….…………………………………………............................………………….....……

……………………………………………………………………………………………………………………………………………........……....................……………………...

|  |  |  |  |
| --- | --- | --- | --- |
| Focus group  Interviews | * Questionnaire/Survey * Documents and records | * Observation * Ethnographies/Oral |    |
| Others *(Specify)* |  | history/Case studies |  |

................……………………………………………………… ……………………………………...........................………………….................................................. If it is an interview, will there be audio-video recording of participants’ interview? If yes, justify the reasons and storage strategies. Yes  No 

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Type of informed consent used in the study.

Individual consent  Gate-keeper consent  Community consent 

Others  *(specify)*....................................................................................................................................................

1. Provide details of safeguards to ensure privacy and confidentiality of participants in the event of data sharing.

................……………………………………………………………………………………………...........................………………….................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Describe strategies to manage if any patterns of behaviour of self-harm or harm to the society are identified.(e.g.: Suicide or infanticide) Yes  No  NA 

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Are cultural norms/Social considerations/Sensitivities taken into account while designing the study and participant recruitment? Yes  No 
2. Is there a use of an interpreter? If yes, describe the selection process. Yes  No  NA 

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

*Version 2.0*

1. Describe any preparatory work or site preparedness for the study Yes  No  NA 

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. I. Type of risk related to procedures involved in the study

Invasive  Potentially harmful  Emotionally disturbing  Involving disclosure 

Describe the risk minimization strategies.

............……………………………………………………………………………………………...........................…………………..................................................

............……………………………………………………………………………………………...........................…………………..................................................

............……………………………………………………………………………………………...........................…………………..................................................

............……………………………………………………………………………………………...........................…………………..................................................

1. Justify reasons if individual harm is overriding societal benefit. Yes  No  NA 

............……………………………………………………………………………………………...........................…………………..................................................

...........……………………………………………………………………………………………...........................…………………...................................................

...........……………………………………………………………………………………………...........................…………………...................................................

1. Describe how do societal benefits outweigh individual harm.

...........……………………………………………………………………………………………...........................…………………...................................................

...........……………………………………………………………………………………………...........................…………………...................................................

...........……………………………………………………………………………………………...........................…………………...................................................

1. Does the study use incomplete disclosure or active deception or authorized deception? If yes, provide details and rationale for deception. Yes  No 

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

1. Describe the debriefing process that will be used to make participants aware of the incomplete disclosure or deception, including their right to withdraw any record of their participation.

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

................……………………………………………………………………………………………...........................…………………..................................................

Signature of PI: ………………………………………………………………………………………………...............…

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

*Version 2.0*



(Annexure 1.12 (AF 1.12/003/01.0)

Study completion/Final report format

Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur

*(Name of the Institution)* **IEC Ref. No.** *(For office use):*

1. Date of EC approval:

Title of study: ……………………….......…………………………………………………………….…......................…………………………………………………..

…………………………………………………………………………………………………………………………………………………............................……………………

……………………………………………………………………………………………………………………………………………............................………………………… Principal Investigator (Name, Designation and Affiliation): ……………………………………...................……………………………………..

……………………………………………………………………………………………………………………………………………............................…………………………

……………………………………………………………………………………………………………………………………………........……....................……………………

1. Date of start of study:

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

1. Provide details of:

Date of study completion:

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

* 1. Total number of study participants approved by the EC for recruitment: ……………………….............................…………………

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

b) Total number of study participants recruited: …………………………………………………….………….................................…………………

c) Total number of participants withdrawn from the study (if any): ……………………………................................…………………..

Provide the reasons for withdrawal of participants23 : ………………………………………………………................................………………….

………………………………………………………………………………………………….......................................…………………………………………………….........

………………………………………………………………………………………………….......................................…………………………………………………….........

1. Describe in brief the publication/ presentation/dissemination plans of the study findings. (Also, mention if both positive and negative results will be shared) …............................................................……………………………………………………………

………………………………………………………………………………………………….......................................…………………………………………………….........

………………………………………………………………………………………………….......................................…………………………………………………….........

1. Describe the main ethical issues encountered in the study (if any) ………………………………………..............................………………

………………………………………………………………………………………………….......................................…………………………………………………….........

………………………………………………………………………………………………….......................................…………………………………………………….........

………………………………………………………………………………………………….......................................…………………………………………………….........

………………………………………………………………………………………………….......................................…………………………………………………….........

1. State the number (if any) of Deviations/Violations/ Amendments made to the study protocol during the study period Deviations: …………………….........…………….. Violation: ……………………...........………… Amendments: …………………….........……….

7. Describe in brief plans for archival of records / record retention:………………..……………...............................………………………….

………………………………………………………………………………………………….......................................…………………………………………………….........

………………………………………………………………………………………………….......................................…………………………………………………….........

………………………………………………………………………………………………….......................................…………………………………………………….........

………………………………………………………………………………………………….......................................…………………………………….………………........

Logo of the Institute

*23 Explanation for the withdrawal of participants whether by self or by the PI*

*Version 2.0*

1. Is there a plan for post study follow-up? Yes  No

If yes, describe in brief: …………………………………………………………………………..........................................………………….……………………..

………………………………………………………………………………………………….......................................…………………………………….……………….........

………………………………………………………………………………………………….......................................…………………………………….……………….........

………………………………………………………………………………………………….......................................…………………………………….……………….........

………………………………………………………………………………………………….......................................…………………………………….……………….........

1. Do you have plans for ensuring that the data from the study can be shared/ accessed easily? Yes  No If yes, describe in brief: ………………………………………………………………..................................................................................………………..

………………………………………………………………………………………………….......................................……………………………………....…………….........

………………………………………………………………………………………………….......................................……………………………………….…………….........

………………………………………………………………………………………………….......................................……………………………………….…………….........

………………………………………………………………………………………………….......................................………………………………………..……………........

1. Is there a plan for post study benefit sharing with the study participants? Yes  No If yes, describe in brief: …………………………………....................................…………………………………………………………………..…………………..

………………………………………………………………………………………………….......................................………………………………………….………….........

………………………………………………………………………………………………….......................................………………………………………….………….........

………………………………………………………………………………………………….......................................………………………………………….………….........

………………………………………………………………………………………………….......................................………………………………………….………….........

11. Describe results (summary) with Conclusion 24 : ………………………………....................................……………………………….…………………

………………………………………………………………………………………………….......................................………………………………………….………….........

………………………………………………………………………………………………….......................................………………………………………….………….........

………………………………………………………………………………………………….......................................………………………………………….………….........

………………………………………………………………………………………………….......................................………………………………………….………….........

12. Number of SAEs that occurred in the study: …………………………..................................…………………………………………….………………..

1. Have all SAEs been intimated to the EC ? Yes  No
2. Is medical management or compensation for SAE provided to the participants? Yes  No If yes, provide details……………………………………………………………………………............……….…………………………………………….…………..…..

………………………………………………………………………………………………….......................................…………………………………………….……….........

………………………………………………………………………………………………….......................................…………………………………………….……….........

………………………………………………………………………………………………….......................................…………………………………………….……….........

………………………………………………………………………………………………….......................................…………………………………………….……….........

Signature of PI: …………………………………………………………………………………….

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

*24 For sponsored studies, if the final report is not available from sponsor, it may be submitted later to the EC once it is ready.*

*Version 2.0*



Logo of the Institute

(Annexure 1.13 (AF 1.13/003/01.0)

Format for Curriculum Vitae for Investigators

Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur

*(Name of the Institution)* **IEC Ref. No.** *(For office use):*

|  |
| --- |
| Name: |
| Present affiliation *(Job title, department, and organisation)*: |
| Address (Full work address): |
| Telephone number: Email address: |
| Qualifications: |
| Professional registration *(Name of body, registration number and date of registration):* |
| Previous and other affiliations *(Include previous affiliations in the last 5 years and other current affiliations):* |
| Projects undertaken in the last 5 years: |

*Version 2.0*

Relevant research training/experience in the area 25 :

Relevant publications *(Give references to all relevant publications in the last five years):*

Signature Date:

*25 Details of any relevant training in the design or conduct of research, for example in the Ethics Training, Human participants’ protection courses, Clinical Trials Regulations, Good Clinical Practice, consent, research ethics training or other training appropriate to non-clinical research. Give the date of the training*

*Version 2.0*